Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

December 30, 2022

Primary Completion Date

April 30, 2025

Study Completion Date

February 28, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

SHR-A1921;

Drug: SHR-A1921 administered as an IV infusion Drug: Adebrelimab administered as an IV infusion Drug: Carboplatin administered as an IV infusion Drug: Cisplatin administered as an IV infusion Drug: Bevacizumab administered as an IV infusion

Trial Locations (1)

300060

Tianjin Medical University Cancer Institute& Hospital, Tianjin

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT05765032 - Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter